Abstracts tagged "innate immunity"

Abstract Number: 0964 • ACR Convergence 2024
Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model
Maithri Aspari¹, Voon Ong², Klaus Soendergaard³, Esben Naeser⁴, Malene Hvid⁴, Angela Tam⁵, Shiwen Xu⁵, Christopher Denton⁶, David Abraham⁷, Bent Deleuran¹ and Stinne Greisen⁸, ¹Aarhus University, Aarhus, Denmark, ²University College London, London, England, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴AARHUS UNIVERSITET, AARHUS C, Denmark, ⁵University College London, London, United Kingdom, ⁶University College London, Northwood, United Kingdom, ⁷UCL, London, United Kingdom, ⁸Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
Abstract Number: 2542 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Anders Nguyen¹, Miriam Bollmann¹, Agnieszka Lastowska², Anna-Karin Hultgård Ekwall¹, Dietmar Zaiss³, Gary Firestein⁴ and Mattias Svensson⁵, ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Goteborg, Sweden, ³University Hospital Regensburg, Regensburg, Germany, ⁴University of California, San Diego, San Diego, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…
Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Hadijat Makinde¹, Miranda Gurra¹, Salina Dominguez², Matthew Dapas², Tyler Therron², Kathleen Aren³, Marie-Pier Tetreault², Monique Hinchcliff⁴, Deborah Winter⁵ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
Abstract Number: 1701 • ACR Convergence 2024
STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Hyun Hee Kim¹, Haochen Jiang², Tatiana Ort³, Gary Sims³ and Richard Hanna⁴, ¹AstraZeneca, Gaithersburg, MD, ²University of Nebraska, Omaha, NE, ³Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Dickerson, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
Abstract Number: 1712 • ACR Convergence 2024
Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment
Yulong Tang¹, Jiangnan Xie², Dachun Zhuo¹, Qi ZHU³, Jiucun Wang¹ and Jing Liu², ¹Fudan University, Shanghai, China (People's Republic), ²Fudan University, Shanghai, Shanghai, China (People's Republic), ³Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
Abstract Number: 1766 • ACR Convergence 2024
STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Conor Gruber¹, Angelica Lee², Sofija Buta², Marta Martin Fernandez², Veronique Houdouin³, Jean-Laurent Casanova⁴, Alice Hadchouel⁵, Jacinta Bustamante⁵ and Dusan Bogunovic², ¹Mount Sinai Hospital, New York, NY, ²Columbia University, New York, NY, ³Robert Debré Hospital, Paris, France, ⁴Rockefeller University, New York, NY, ⁵Hôpital Necker-Enfants Malades, Paris, France
Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 1796 • ACR Convergence 2024
Kidney Hematopoietic Stem and Progenitor Cells Contribute to Immune Cell Development and Pathology in Lupus Nephritis
Hansol Yi¹, Seyoung Jung², Mi-Ra Cho³, Yong-Gil Kim¹, Chang-Keun Lee¹, Bin Yoo¹, Jeongseok Lee² and Seokchan Hong¹, ¹Asan medical center, Seoul, Republic of Korea, ²Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Background/Purpose: Hematopoiesis primarily occurs in the bone marrow (BM), where hematopoietic stem and progenitor cells (HSPCs) originate. However, non-lymphoid tissues outside the BM can contribute…
Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Gary Sims¹, Mia Collins², Natalie Pursell³, Teneema Kuriakose¹, Fanyi Jiang⁴, Kristi Moore⁵, Lucie Bertrand⁵, Melissa Lasaro⁵, Jessica Neisen⁶, Scott Manetz⁷, Gabriel Wong⁸, Patrick Riley⁵, Iain McInnes⁹, Kyriakos Konstantinidis¹⁰ and David Close⁸, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Dicerna, Lexington, ⁴Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁵Alexion, AstraZeneca Rare Disease, New Haven, CT, ⁶Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹⁰Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
Abstract Number: 1816 • ACR Convergence 2024
Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages
Emily Morris¹, Helen Jarnagin², Heetaek Yang³, Alexandra Turnquist², Michael Whitfield⁴ and Patricia Pioli⁵, ¹Dartmouth College, Enfield, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth College, West Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: While we have shown that systemic sclerosis (SSc) dermal fibroblasts and macrophages (MØs) engage in reciprocal activation mediated by exosomes via paracrine signaling, the…
Abstract Number: 0046 • ACR Convergence 2024
Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
Jeba Atkia Maisha¹, Alina Sememenko², Jun Kim², Mario Navarrete², XIAOBO MENG¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Juliette Ferrant¹, Alain Lescoat², Valérie Lecureur³, Marie Lelong³, John Varga⁴, Robert Lafyatis⁵, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹CHU Rennes, Rennes, France, ²CHU Rennes - University Rennes 1, Rennes, France, ³Rennes University, Rennes, France, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
Abstract Number: L02 • ACR Convergence 2023
Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
John Huizar¹, Victoria Rael², Julian Yano², Leianna Slayden³, Madeleine Weiss⁴, Robert Saxton⁴, Bo Liu⁵, Olivia Majer⁶ and Gregory Barton⁷, ¹UCSF, San Francisco, CA, ²Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, UC Berkeley, Berkeley, CA, ³HHMI at UC Berkeley, Berkeley, CA, ⁴UC Berkeley, Berkeley, CA, ⁵Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangai, China, ⁶Max Planck Institute for Infection Biology, Berlin, Germany, ⁷UC Berkeley / HHMI, Berkeley, CA
Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…
Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Leonie Middelink¹, Renato Chirivi², Helmuth van Es², Eric Meldrum², Peter van Zandvoort², Tirza Bruurmijn², Matthijs Moerland³ and Patrick Round², ¹Middelinc., Utrecht, Netherlands, ²Citryll BV, Oss, Netherlands, ³CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…
Abstract Number: 0050 • ACR Convergence 2023
Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Maarten van der Linden¹, Sangeeta Kumari¹, Daphne Montizaan¹, Stephanie van Dalen¹, Annemarie Kip¹, Martyn FOSTER², Inge Reinieren¹, Elsa Neubert³, Luise Erpenbeck⁴, Tirza Bruurmijn¹, Peter van Zandvoort¹, Paul Vink¹, Eric Meldrum⁵, Helmuth van Es¹ and Renato Chirivi¹, ¹Citryll BV, Oss, Netherlands, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³Leiden Academic Centre for Drug Research, Leiden, Netherlands, ⁴University Medical Center Münster, General Dermatology and Venereology, Münster, Germany, ⁵Citryll BV, Basel, Switzerland
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].